Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 8/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.58 |
| ▸ | MET | P08581 | 6/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064400 | 0.87 | MET (0.60) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL28428907 | 0.85 | PDGFRA (0.55) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL2062688 | 0.82 | PDGFRA (0.71) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL2172904 | 0.80 | PDGFRA (0.64) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL4141201 | 0.79 | FGFR2 (0.59) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL2063576 | 0.78 | FGFR2 (0.64) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL7487378 | 0.78 | FGFR2 (0.77) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL2465380 | 0.78 | PDGFRA (0.71) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL17489704 | 0.78 | PDGFRA (0.65) | PDGFRAKDRFGFR2SRCTGFBR1 | |
| SCHEMBL2176021 | 0.77 | PDGFRA (0.61) | PDGFRAKDRMETKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1877383-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | PDGFRA 3858/4885KDR 3088/4885MET 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.